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Abstract  
Gestational choriocarcinoma is a malignant tumour derived from placental trophoblast and the most 
aggressive member of gestational trophoblastic disease (GTD). Apoptotic stimulating protein of p53-2 
(ASPP2) is a member of ASPP family that transactivates p53 and thereby functions as a tumour 
suppressor. In this study, the expression profile of ASPP2 in choriocarcinoma was examined in 
comparison with normal placentas and hydatidiform moles, the latter being a type of GTD that carries 
malignant potential. Downregulation of ASPP2 mRNA and protein was demonstrated in 
choriocarcinoma by quantitative PCR and immunohistochemistry. ASPP2-transfected 
choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell 
migration as detected by TUNEL and wound healing assays, respectively, illustrating the complex 
action of ASPP2 on cell functions other than programmed cell death. Activated Src is known to be 
important in tumour progression. Transfection of ASPP2 but not ASPP1, another tumour suppressive 
ASPP, was found to be related to subsequent decreased Src-pY416 phosphorylation, suggesting an 
inactivating effect of ASPP2 on Src. Moreover, this ASPP2-mediated inactivation of Src could be 
abolished by RNA interference with Csk, a kinase that can inhibit Src activation. Our findings 
suggested that the ability of ASPP2 to attenuate Src activation was specific to ASPP2 in a Csk 
dependent manner. Taken together, we demonstrated a loss of tumour suppressive ASPP2 in 
choriocarcinoma with effects on cell migration as well as apoptosis. We also unveiled a possible 
mechanistic link between ASPP2 and Csk/Src signaling pathway, implicating the multiple cellular 
functions of ASPP2. 
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Introduction  
Choriocarcinoma is a prominent member of gestational trophoblastic disease (GTD) which 
encompasses a heterogeneous family of allografts arising from placental trophoblasts with varying 
potential for local invasion and metastasis [1,2]. GTD can be classified into premalignant hydatidiform 
moles and frankly malignant tumours like choriocarcinoma, placental site trophoblastic tumour (PSTT) 
and epithelioid trophoblastic tumour (ETT). Hydatidiform moles, including partial and complete moles, 
often regress after suction evacuation although around 20% of cases progress to persistent 
gestational trophoblastic neoplasia requiring chemotherapy [3]. In contrast, choriocarcinoma, the most 
malignant lesion in GTD, is characterized by massive trophoblastic tissue invasion and vascular 
permeation leading to haemorrhagic metastasis [4,5].  
Unlike other solid tumours, classical tumour suppressor genes p53, RB1 and p21 were found to 
be upregulated in choriocarcnoma [6]. The increased expression of these tumour suppressors may 
represent inherent but failed mechanisms to antagonize the overgrowth and excessive proliferative 
activity in the trophoblast cells. On the other hand, loss or reduced expression of a panel of tumour 
suppressors has also been reported. For example, p16, E-cadherin, and TIMP3 were downregulated 
in choriocarcinoma through promoter hypermethylation [7,8]. Restoration of certain tumour 
suppressor in choriocarcinoma may alter the tumour cell phenotype. For instance, ectopic NECC1 
(not expressed in choriocarcinoma clone 1) could suppress the tumorigenicity and induced 
differentiation of choriocarcinoma cells [9]. Thus, a unique profile of alternations in tumour suppressor 
expression appears to contribute to the malignant phenotype of choriocarcinoma.  
Apoptosis stimulating protein of p53 (ASPP) is a family of p53 binding proteins which shares a 
common feature containing an Ankyrin repeat domain, a SH3 domain, and a Poly-Proline rich domain 
at the C-terminus [10]. To date, three family members, namely ASPP1, ASPP2 and iASPP have been 
identified. Our recent report on downregulation of proapoptotic ASPP1 in association with clinical 
progression of GTD uncovers the importance of ASPP family in the disease development [11]. 
Similar to ASPP1, ASPP2 is a proapoptotic regulator that belongs to ASPP family. The 
expression of ASPP2 is frequently suppressed in many cancers in relation to enhanced apoptosis 
through the binding to p53 for transcriptional transactivation [12-14]. The interaction and regulation of 
p53 by the ASPP family members seems to be evolutionarily conserved. Homologs of ASPP family 
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members have been identified in C. elegan (ape-1) and Drosophila (dASPP) [15,16]. Surprisingly, a 
number of ASPP2 binding partners that are involved in biological pathways other than apoptosis have 
also been identified, suggesting that ASPP2 function is far more complex than simply enhancing p53-
mediated apoptosis [17]. Abnormal activation of Src-family kinases has been implicated in a wide 
variety of cancers and is associated with tumour metastasis [18]. A recent study has found that 
Drosophila ASPP (dASPP) could maintain epithelial integrity through physical interaction with C-
terminal Src kinase (Csk) to augment the inhibitory phosphorylation of Drosophila Src (dSrc) [16]. 
However, little is known about these interactions in human and the corresponding biological 
significance in cancer cells has not been reported.  
In this study, we investigated the expression profile of ASPP2 in GTD, the effects of ASPP2 on 
apoptosis, cell migration and the Src signaling pathway. 
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Materials and methods 
Clinical samples and cell lines 
A total 94 trophoblastic tissues, including 20 first trimester placentas, 12 term placentas, 15 partial 
moles, 35 complete moles, 12 choriocarcinomas were retrieved from the archives of Department of 
Pathology, Queen Mary Hospital, The University of Hong Kong. All tissue sections were histologically 
reviewed using generally agreed and accepted diagnostic criteria [1]. First trimester and term placenta 
were collected after induced abortion by suction evacuation and normal delivery respectively. The 
tissues of hydatidiform moles and choriocarcinomas were obtained from specimens of uterine 
evacuate and/or hysterectomy.  
Ethics approval for the use of such tissues in this study has been obtained from Institutional 
Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. The 
experimental results were delinked from subjects’ personal information and individual’s consent was 
considered not necessary. The need for written informed consent from the participants was waived by 
the Institutional Review Board. 
The clinical diagnosis of persistent gestational trophoblastic neoplasia was made if there was a 
plateau in human chorionic gonadotrophin (hCG) level for 4 weeks or a further rise in hCG for three 
consecutive weeks after evacuation. In most of the cases, the diagnosis of hydatidiform moles had 
been confirmed by fluorescent microsatellite genotyping after microdissection and chromosome in situ 
hybridization [19,20]. These trophoblastic tissues ha e also been assessed earlier by 
immunohistochemical studies using M30 Cytodeath (Boehringer Mannheim, Mannheim, German) [21] 
and p53 (DO-7, Novocastra Laboratories Ltd., Newcastle, UK) antibodies [22].  
For in vitro studies, two choriocarcinoma cell lines (JEG-3 and JAR) (American Type Culture 
Collection, Manassas, VA, USA) were cultured in Minimum Essential Eagle’s Medium (Sigma, St 
Louis, MO, USA) supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), 
and 100 U/ml penicillin and streptomycin (Invitrogen, San Diego, CA, USA)[23]. Normal trophoblast 
cell lines B6 and PE4 are kind gifts from Professor George S. W. Tsao (the Department of anatomy, 
the University of Hong Kong). 
 
Immunohistochemical study 
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Paraffin sections 5 µm thick were cut and deparaffinized. Antigen retrieval was carried out at 
95 °C for 10 min in 10 mM sodium citrate buffer at pH 6.0. Immunohistochemistry was performed 
using the UltraVision LP Value Detection System Horseradish Peroxidase (HRP) Polymer (LabVision, 
Fremont, CA, USA)[24]. A monoclonal mouse anti-human antibody of ASPP2 (Clone DX 54.10) 
(Sigma, St.Louis, MO) was applied in 1:1500 dilution and incubated overnight at room temperature. 
Freshly-prepared 3.3’-diaminobenzidine tetrahydrochloride (DAB) (Amresco, Solon, Ohio) in PBS with 
hydrogen peroxide was applied as chromagen and sections were counter-stained with hematoxylin. 
Negative controls were prepared by replacing the primary antibody with PBS. A known positive 
control from a normal first trimester placenta was used. The percentage of ASPP2 immunopositive 
cells was scored according to the following criteria: 0, negative; 1, 0.1–25.0% of cells immunopositive; 
2, 25.1–50.0% immunopositive; 3, 50.1–75.0% immunopositive; 4, 75.1–100% of cells 
immunopositive [24,25]. ASPP2 immunoreactivity was further correlated with p53 expression [22]. 
 
Quantitative Real-time PCR  
Trizol reagent (Invitrogen, Life Technologies Inc, Rockville, MD) was used for total RNA 
extraction according to the manufacturer’s instruction. First strand cDNA was synthesized from 2.5 µg 
total RNA by SuperScript Reverse Transcriptase system (Invitrogen). Primers used were as followed: 
ASPP2 (Forward: 5’-GTG CTG CCT CAT GTA ACA AC-3’; Reverse: 5’-TAT GCC CAT CTT CTC 
CTG AAC-3’) and GAPDH (Forward: 5’-TCC ATG ACA ACT TTGGTA TCG CG-3’; Reverse: 5’-ACA 
GTC TTC TGG GTG GCA GTG-3’). Quantitative PCR (qPCR) was performed on the ABI PRISM 
7900 Sequence Detection System (Applied Biosystems, Foster City, CA). The expression of ASPP2 
determined by 2
-∆∆CT
 method was normalized with respected to that of GAPDH. 
  
Transfection and Western blot analysis 
JEG-3 and JAR culture in 6-well plates were transfected with either ASPP2 and ASPP1 construct 
(generous gift from Prof. Xin Lu of Ludwig Institute for Cancer Research, UK) using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). The pCDNA 3.1 vector was used as control. Total protein lysate was 
extracted with lysis buffer (0.125 M Tris, pH 6.8 at 22ºC containing 1% NP-40 [v/v], 2 mM EDTA, 2 
mM phenylmethylsulfonyl fluoride, 1 mM sodium  orthovanadate and 0.1 µM sodium okadate). Protein 
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concentration was determined by detergent compatible protein assay (Bio-Rad Laboratories, Hercules, 
CA). Twenty µg of protein was resolved by SDS-polyacrylamide gel electrophoresis and then 
transferred to polyvinylidene difuoride membrane and probed with corresponding antibodies [25]. 
Primary antibodies used in this study were listed in Table 1.  
 
TdT-Mediated dUTP Nick End Labeling Assay  
TdT-mediated dUTP nick end labeling assay (TUNEL) was performed using an In Situ Cell Death 
Detection kit (Roche Biochemical, Indianapolis, IN) as previously described [21]. The number of 
TUNEL-positive cells in different controls and in JEG-3 and JAR after ASPP2 transient transfection 
was counted in three different fields at Χ40 magnification by fluorescence microscopy. 
  
Silencing of Csk by small interfering RNA (siRNA) 
To knockdown Csk in choriocarcinoma cell line, Silencer® select Pre-designed siRNA of Csk 
(siCsk) (Cat: 4427037; ID:s3614) and non-targeting Negative Control   #2 (scramble) siRNA (Cat: 
43900846) were used (Ambion, Austin, TX). Co-transfection with 5 nM Csk-specific/non-targeting 
siRNA and empty vector pCDNA3.1/ ASPP2 construct in Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) was carried in 6-well culture plate. To assess the knockdown efficiency, Western blotting was 
performed using the protein lysate harvested 48 h post-transfection. 
  
Wound healing assay 
Migration of the cells was determined by wound healing assay. Cells were first transfected with 
specified plasmid constructs or siRNA oligo for one day in twelve-well plates with 90% confluence. 
The treated cell monolayer was then scratched with a sterile 200-µl pipette tip.  Fresh culturing 
medium was added. Photos were retaken at the same position of the wound after 48 hours. Results 
expressed in percentage to control were defined as the average percentage change in linear wound 
closure in treatment with respect to that in control. 
 
Statistical analysis 
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Statistical analysis was performed using the Statistical Package for Social Science (SPSS) 15.1. 
Non-parametric unpaired t-test (Mann-Whitney test) was used for continuous data. Spearman’s rho 
test was used for correlation analysis. P values <0.05 were considered as statistically significant. 
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Results 
Downregulated expression of ASPP2 mRNA and protein in choriocarcinoma 
By qPCR analysis, ASPP2 mRNA was found to be downregulated in choriocarcinoma cell lines, 
JEG-3 and JAR, when compared with normal trophoblast cell lines, B6 and PE (Figure. 1A). 
Significantly lower ASPP2 mRNA was also detected in choriocarcinoma samples compared with 
normal first trimester placenta (P = 0.012). Hydatidiform moles showed an intermediate ASPP2 
mRNA expression between normal placentas and choriocarcinomas (Figure 1B).  
By immunohistochemistry, both nuclear and cytoplasmic ASPP2 expression was detected in first 
trimester samples. ASPP2 was found to be expressed predominantly in the nucleus and moderately 
in the cytoplasm of cytotrophoblasts and villous intermediate trophoblasts of normal placenta and 
hydatidiform moles in contrast to the absence of expression in choriocarcinoma (Figure 1C - F). 
Immunoreactivity to ASPP2 in PSTT was also weak. Moreover, no nuclear immunoreactivity could be 
detected in the syncytiotrophoblasts. Concurring with the qPCR findings, significantly lower ASPP2 
immunoreactivity was found in the choriocarcinoma compared with normal first trimester samples (P < 
0.001, Mann–Whitney test; Figure 1G). There was no significant difference in immunoreactivity 
between hydatidiform moles that subsequently developed GTN (progressed mole) and those that 
spontaneously regressed (P = 0.786, Mann–Whitney test). Although both regressed and persistent 
hydatidiform moles showed a lower nuclear immunoreactivity than normal first trimester placenta, no 
statistical significance was reached (P = 0.06 and 0.42 respectively; Figure 1G).  
 
Ectopic ASPP2 increased apoptosis but reduced cell migration in choriocarcinoma cells 
Retrieval of data from corresponding cases showed that nuclear immunoreactivity of ASPP2 
correlated inversely with p53 (P = 0.032, coefficient= -0.301, Spearman's ρ test) [22]. Such correlation 
suggested that loss of ASPP2 in choriocarinoma could modify p53 activity leading to difference in 
apoptotic activity among GTD. The effect of ASPP2 on apoptosis in choriocarinoma was assessed by 
ASPP2 transfection and TUNEL assay. Our results showed that ectopic ASPP2 expression increased 
percentage of apoptotic cells from 2.6+1.9% to 10.5+2.7% in JEG-3 (Figure 2A) and 3.5+2.9 to 
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14.0+3.7% in JAR (Figure 2B) cells in contrast to control respectively (Figure 2), suggesting that loss 
of proapoptotic ASPP2 could attenuate apoptosis in choriocarcinoma cells. 
By wound healing assay, slower migration rate was found in JEG-3 transfected with ASPP2 than 
those transfected with ASPP1 or the control (Figure 3A, left panel). Our results demonstrated, for the 
first time, that ASPP2 negatively regulate cell migration in choriocarcinoma. Furthermore, western blot 
analysis also showed an ASPP2-specific induction of E-cadherin expression (Figure 3A, right panel). 
 
ASPP2-specific inactivation of Src  
In view of the multi-functional nature of ASPP2 with effect on both apoptosis and cell migration 
in choriocarcinoma cells, possible interaction between ASPP2 and Src signaling pathway was 
evaluated. Activation and inactivation of Src is known to be tightly regulated by phosphorylation at two 
sites with opposite effects. Phosphorylation site at Tyr416 (Y416) in the activation loop of the kinase 
domain contributes to augmentation of Src activity. In contrary, Csk-mediated phosphorylation of                         
Tyr527 (Y527) at C-terminal tail of Src results in a closed structure, through intramolecular interaction 
with its SH2 domain, that diminishes the access of substrates to the kinase domain and prevent Y416 
autophosphorylation [26]. As shown in Figure 3B, overexpression of ASPP2 in both JEG-3 and JAR 
could reduce the expression level of Src-pY416, an activated form of Src. However, such observation 
was not found in cells transfected with ASPP1, another member of the ASPP family exerting tumour 
suppressive effect. Moreover, complementary increased phosphorylation at inhibitory domain Src-
pY527 accompanied with ectopic ASPP2 expression was also demonstrated. The total form of Src 
remained unchanged after ASPP2 or ASPP1 transfection. 
 
Csk-knockdown abolished the ASPP2 effect on Src inactivation and cell migration inhibition 
The above findings suggested that ASPP2 may negatively regulate cell migration through 
Csk/Src signaling pathway in choriocarcinoma cells. To unveil the mechanistic action of this potential 
interaction, ASPP2 and Csk-specific siRNA were cotransfected in JEG-3 cells for downstream 
analysis. As shown in figure 4A, in the presence of scramble siRNA, ectopic ASPP2 expression 
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inactivate Src as indicated by suppressing the expression of Src-pY416 and was also able to induce 
E-cadherin expression in JEG-3. In contrast, such inactivation and induced E-cadherin expression 
were abolished when the JEG-3 cells underwent co-transfection of ASPP2 and Csk siRNA. More 
importantly, inhibitory effect on choriocarcinoma cell migration by ectopic ASPP2 was also eliminated 
after Csk-specific knockdown as demonstrated in wound healing assay (Figure 4B). 
As the Y527 inhibitory phosphorylation site is mediated by Csk, our results demonstrated that 
Src could be inactivated specifically by ASPP2 through the action of Csk with effects of cell migration. 
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Discussion 
In this study, we have revealed a choriocarcinoma specific loss of ASPP2 compared with normal 
placentas and GTD subtypes and a pleiotropic nature of ASPP2 which, in addition to stimulating 
apoptosis, negatively regulate cell migration through Src signaling pathway in a Csk dependent 
manner. Human trophoblasts exert a crucial role in implantation and placentation of pregnancy and 
fetal development. Alterations in molecular mechanism and signal transduction pathways on 
trophoblast cell migration and its invasiveness may lead to pathological conditions [27,28]. As 
choriocarcinoma is the malignant extreme of the spectrum of GTD, our present data identifies a 
critical role of ASPP2 in tumourigenesis of choriocarcinoma with its effects in apoptosis and cell 
migration. 
Apoptosis is an important process in pathogenesis in GTD [21,24,29,30]. Studies on p53 related 
genes and modulation of p53 activity may help understand the development of GTD. ASPP2 is 
originally identified as a p53 binding protein. It has been demonstrated that ASPP2 is able to induce 
apoptosis through mitochondrial pathway associated with activation of caspase-9 [31]. Our results in 
apoptosis in choriocarcinoma cells concur with the central role of ASPP2 in the regulation of 
apoptosis as described in these studies.  
Real time qPCR showed a downregulation of ASPP2 mRNA level in hydatidiform mole and 
choriocarcinoma respectively compared with normal placenta (Figure 1B). Normal placental chorionic 
villi are composed of a complex and heterogeneous population of trophoblast cells, including 
cytotrophoblast, syncytiotrophoblast and villous intermediate trophoblast. Specific spatial and 
subcellular alteration of ASPP2 expression was further evaluated by immunohistochemistry. Since 
cytotrophoblast is the progenitor of villous trophoblasts and syncytiotrophoblast [32] and is regarded 
as critical for neoplastic transformation in trophoblastic tumours [3], we specifically assessed the 
immunoreactivity of nuclear ASPP2 in cytotrophoblast as a function of p53 transactivation (Figure 1G). 
Loss of nuclear ASPP2 immunoreactivity particularly in the truly malignant choriocarcinoma concurs 
with the fact that choriocarcinoma has a lower apoptotic activity than premalignant hydatidiform moles 
as we reported previously [21,29]. Besides the expression in nuclei, cytoplasmic immunoreactivity of 
ASPP2 was also detected in both first trimester placenta and hydatidiform mole samples. In contrast, 
in choriocarcinoma and PSTT, the malignant forms of GTD, total loss or very weak ASPP2 expression 
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in both the nucleus and cytoplasm was observed, respectively. Such findings suggested a possible 
interaction between cytoplasmic ASPP2 protein and gene products that are responsible for cellular 
functions other than apoptosis, and may therefore account for the aggressiveness of choriocarcinoma 
or PSTT.  
Although Drosophila homolog of ASPP (dASPP) has been reported to interact with dCsk to 
regulate dSrc kinase to maintain epithelial integrity [16], biological significance regarding interaction 
between Src signaling pathway and ASPP family members are not available in humans. Our data on 
RNA interference and Western blot analysis clearly showed that ectopic ASPP2 could inactivate Src 
signaling in a Csk dependent manner in choriocarcinoma cells and reported for the first time the ability 
of ASPP2 to negatively regulate cell migration through the Csk/Src axis. Indeed, a wide body of 
evidences has shown that activated Src kinase endows migratory phenotype through interaction with 
a number of downstream signaling pathways including FAK, paxillin, ERK as well as internalization of 
E-cadherin [18,33,34]. As a result, ASPP2 mediated cell migration through Csk/Src axis is noteworthy 
to be further investigated in cancer biology. 
Metastasis is a multi-step process and is usually initiated by detachments of tumour cells from 
primary sites [35,36]. E-cadherin is an extensively studied cell adhesion molecule which mediates cell 
adhesion in a homotypic manner [36].  Suppression of E-cadherin expression is frequently involved in 
human cancers and is considered as one of the early events of tumourigenesis [37]. Our lab has 
earlier reported that E-cadherin is down-regulated by hypermethylation in GTD and choriocarcinoma 
has the lowest level of expression [38]. Interestingly, increased Src activity is known to reduce cell-cell 
adhesion by promoting the internalization and ubiquitin-mediated protein degradation of E-cadherin 
[39,40]. Moreover, Src specific inhibitor PP2 enhanced E-cadherin expression at transcript and 
protein levels [41]. These actions exemplify the upregulation of E-cadherin through reduced protein 
degradation and increased transcript expression upon Src inactivation. Consistent with ASPP2-
specific interaction with Csk/Src axis demonstrated in this study, E-cadherin expression could be 
specifically induced by ectopic ASPP2 in JEG-3 cells whilst this induction was abolished under Csk-
knockdown (Figure 4A). Hence, transfected ASPP2 inactivated Src activity, through which E-cadherin 
was upregulated and subsequently accumulated in the cells. Taken together, loss of ASPP2 could 
work as an additional mechanism to further down-regulate E-cadherin expression, leading to loss of 
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cell-cell adhesions and, at least in part, contributing to the aggressive and malignant phenotype of 
choriocarcinoma. 
Unlike ASPP2, another ASPP family member ASPP1 failed to inactivate Src as illustrated by the 
decreased expression of Src-pY416. This observation was consistently demonstrated in both JEG-3 
and JAR cell lines. While it has been proposed that the interaction between ASPP proteins and Src is 
commonly evolutionary conserved from Drosophila to humans [16,42], our in vitro study clearly 
indicated that ASPP2, but not ASPP1, interact with Csk/Src axis and highlighted an ASPP2-specific 
regulation of cell migration through this signal transduction pathway. Indeed, a recent study showed 
that knockdown of ASPP2 was more effective in promoting the growth of hepatocellular carcinoma 
cells both in soft-agar transformation assay and in nude mice, when compared with that of ASPP1 
[14]. Thus, the loss of ASPP2 might exert a more potent effect than ASPP1 in tumour development 
with respect to the pleiotropic nature of this tumour suppressor. 
 In conclusion, we found loss of expression of the multi-functional ASPP2 in choriocarcinoma 
but not the premalignant hydatidiform moles, suggesting its crucial role in tumourigenesis through its 
effect on inhibiting cell migration and promoting apoptosis. An ASPP2-specific inactivation of the 
oncogenic Src in a Csk dependent manner was further demonstrated, which provides a mechanistic 
link between loss of ASPP2 and the aggressive phenotype of choriocarcinoma at molecular basis. 
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TABLE  
Table 1. Primary Antibodies Used for Immunoblotting 
 
FIGURE LEGENDS 
Figure 1 Downregulation of ASPP2 in choriocarcinoma. (A)&(B): Quantitative real-time PCR 
analysis on mRNA expression of ASPP2 between (A) normal trophoblast (PE4, B6) and 
choriocarcinoma (JAR, JEG) cells as well as (B) in normal placentas (1st trimester and Term), 
hydatidiform moles (HM) and choriocarcinoma (CCA) clinical samples. (C)-(G): Immunreactivity of 
ASPP2 in trophoblastic tissues. In normal first trimester placenta (C) and hydatidiform mole (D), both 
nuclear and cytoplasmic staining could be observed in the cytotrophoblast (CT) and villous 
intermediate trophoblast (VIT) whereas predominantly cytoplasmic staining was detected in 
syncytiotrophoblast (ST) (indicated by arrows). Central cistern in enlarged villi in hydatidiform mole 
was marked by asterisk (*). In choricarcinoma (E), which was composed of both CT and ST, loss of 
ASPP2 immunoreactivity was observed. A much weak expression of ASPP2 was also detected in 
PSTT, another trophoblastic malignancy (F). Scale bar, 200 µm. (G): Bar chart illustrating the reduced 
nuclear immunohistoscore of ASPP2 in cytotrophoblast of choriocarcinoma when compared with 
placenta and hydatidiform moles.  
 
Figure 2 ASPP2 induced apoptosis in choriocarcinoma cells. A-B: Photographs of 
representative fields of TUNEL assay in choriocarcinoma cell lines JEG-3 (A) and JAR (B) after empty 
vector (control) and ASPP2 transfection. (C): Percentage of apoptotic cells (apoptotic cells/total cells 
counted) in both cell lines after empty vector (control) and ASPP2 transfection. Approximately 80-100 
cells were analyzed per random high power field of view. 
 
Figure 3 Wound healing assay and ASPP2-specific inactivation of Src. (A): Left panel: Effects of 
ectopic ASPP1 and ASPP2 expression on cell migration in choriocarcinoma cell JEG-3. Right panel: 
Enhanced E-cadherin expression in ASPP1 and ASPP2 transfected JEG-3 cells. (B): Western blot 
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analysis on the effect of ectopic ASPP1 and ASPP2 expression on Src phorspholyation at 
autophosphorylation domain Y416 (activated state) and inhibitory domain Y527 (closed structure).  
 
Figure 4 ASPP2 inactivates Src through Csk. (A): Csk-knockdwon abolished the effect of ectopic 
ASPP2 on Src inactivation. (B): Bar chart showing effect of Csk-knockdwon on cell migration of 
ASPP2 transfected JEG-3 cells as determined by wound healing assay.  
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Table 1 Primary Antibodies Used for Immunoblotting 
Target 
Protein 
Animal 
Source 
Catalog# Working 
dilution 
Vendor 
ASPP2 Mouse A4480 1:500 Sigma (St. Louis, MO) 
Actin Rabbit A5060 1:1000 Sigma 
Csk Rabbit sc-286 1:1000 Santa Cruz biotechnology, 
Inc (Santa Cruz, CA) 
Src Total Mouse sc-8056 1:1000 Santa Cruz biotechnology, 
Inc 
Phospho-Src 
(Tyr416) 
Rabbit 2101 1:1000 Cell Signaling (Beverly, 
MA) 
Phospho-Src 
(Tyr527) 
Rabbit 2105 1:1000 Cell Signaling 
E-cadherin Mouse 610181 1:5000 BD Biosciences (San 
Diego, CA) 
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